The stock gained 6.4% post-earnings, reflecting investor approval of strong net sales growth driven by accelerating Rezdiffra adoption and a rapidly expanding addressable market in MASH.

• Q1 2026 net sales reached $311 million, up 127% year-over-year.
• Active Rezdiffra patients grew to over 42,250, a 2.5x increase from Q1 2025.
• The U.S. diagnosed MASH market expanded nearly 50% since 2023, now estimated at 460,000 patients.
• Rezdiffra penetration remains below 10%, underscoring significant runway ahead.
• Management highlighted a robust data generation strategy with upcoming presentations reinforcing efficacy and cardiovascular risk benefits.